Cardlytics, Inc. (NASDAQ:CDLX) Given Average Recommendation of “Hold” by Brokerages

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have earned a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $6.92.

CDLX has been the topic of several research analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Evercore ISI began coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. Finally, Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th.

Cardlytics Stock Performance

CDLX stock opened at $3.35 on Friday. The firm has a market cap of $170.25 million, a PE ratio of -0.55 and a beta of 1.53. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock has a 50-day moving average price of $3.87 and a 200-day moving average price of $4.76. Cardlytics has a 1-year low of $2.89 and a 1-year high of $20.52.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm’s revenue for the quarter was down 15.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) earnings per share. As a group, equities research analysts expect that Cardlytics will post -1.52 earnings per share for the current year.

Insider Buying and Selling at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. The trade was a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alexis Desieno sold 8,854 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18. Following the sale, the chief financial officer now owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. The trade was a 6.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,007 shares of company stock worth $251,297. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

Several institutional investors and hedge funds have recently bought and sold shares of CDLX. Bank of New York Mellon Corp lifted its position in shares of Cardlytics by 15.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after buying an additional 18,179 shares during the last quarter. Quest Partners LLC boosted its position in Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after purchasing an additional 11,061 shares during the period. ClariVest Asset Management LLC boosted its position in Cardlytics by 48.7% during the second quarter. ClariVest Asset Management LLC now owns 72,546 shares of the company’s stock worth $596,000 after purchasing an additional 23,746 shares during the period. Renaissance Technologies LLC increased its stake in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. purchased a new stake in shares of Cardlytics during the 2nd quarter valued at approximately $243,000. 68.10% of the stock is owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.